Growth Metrics

Eli Lilly (LLY) Total Non-Current Liabilities (2016 - 2026)

Eli Lilly filings provide 18 years of Total Non-Current Liabilities readings, the most recent being $48.7 billion for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 12.12% to $48.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $48.7 billion, a 12.12% increase, with the full-year FY2025 number at $50.7 billion, up 40.61% from a year prior.
  • Total Non-Current Liabilities hit $48.7 billion in Q1 2026 for Eli Lilly, down from $50.7 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $50.9 billion in Q3 2025 to a low of $21.6 billion in Q4 2022.
  • Median Total Non-Current Liabilities over the past 5 years was $31.1 billion (2024), compared with a mean of $33.2 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: fell 18.49% in 2022 and later soared 48.77% in 2024.
  • Eli Lilly's Total Non-Current Liabilities stood at $21.6 billion in 2022, then grew by 19.81% to $25.8 billion in 2023, then soared by 39.53% to $36.1 billion in 2024, then surged by 40.61% to $50.7 billion in 2025, then dropped by 3.88% to $48.7 billion in 2026.
  • The last three reported values for Total Non-Current Liabilities were $48.7 billion (Q1 2026), $50.7 billion (Q4 2025), and $50.9 billion (Q3 2025) per Business Quant data.